Kaiyuan securities released a research report on August 27, saying that it maintained the rating of Guizhou Xinbang Pharmaceutical Co.Ltd(002390) (002390.sz, latest price: 9.59 yuan). The reasons for rating mainly include: 1) H1 revenue and profit increased quarter by quarter, and Q2 Profit increased faster; 2) The core business medical service has great growth potential, and the profitability of Guizhou cancer hospital has been rapidly improved; 3) The equity incentive plan stimulates the motivation of employees and helps the company maintain steady growth. Risk tip: the cost control of medical insurance is becoming more and more strict; The improvement progress of hospital single bed output was less than expected.
AI comments: Guizhou Xinbang Pharmaceutical Co.Ltd(002390) obtained the attention of one Research Report of securities companies in recent month and bought one.
(Daily Economic News)
